To assess the clinical and cost effectiveness of surgery for people with morbid obesity. DESIGN: A systematic review of randomised control trials (RCTs), prospective clinical trials and economic evaluations identified from 14 electronic databases (including Medline, Cochrane library and Embase from their inception to October 2001), bibliographies and consultation with experts and manufacturers was performed to assess the clinical and cost effectiveness of different surgical procedures and nonsurgical management for morbid obesity. An economic evaluation was undertaken to assess cost effectiveness in the UK. SUBJECTS: People diagnosed as morbidly obese, defined as a body mass index (BMI) (weight in kilograms/height in metres 2 ) 440 kg/m 2 , or with a BMI435 kg/m 2 with serious comorbid disease, in whom previous nonsurgical interventions had failed. MEASUREMENTS: The outcomes assessed included weight change, quality of life, peri-and postoperative morbidity and mortality, revision rates and obesity comorbidities. Cost effectiveness was modelled from these data and presented as cost per quality-adjusted life year (QALY). RESULTS: Included studies differed in methodological quality. Surgery resulted in a significantly greater loss of weight (23-37 kg more weight) than nonsurgical treatment, which was maintained to 8 years and led to improvements in quality of life and comorbidities. The economic evaluation of surgery compared with nonsurgical management suggested that surgery was cost effective at d11 000 per QALY. Comparisons of the different types of surgery were equivocal. CONCLUSION: Surgery for morbid obesity appears to be clinically and cost effective. Because of the nature of the evidence, particularly the uncertainty in the clinical and economic evaluations, it is difficult to distinguish between the different surgical procedures.
Introduction
Obesity is an increasing public health problem worldwide. Some 31% of adults aged 20-74 y in USA in 1999-2000 1 and 17% of men and 21% of women in England in 1998 2 were obese (body mass index (BMI)430 kg/m 2 ). Trends among children and adults suggest that the problem will continue to grow. [1] [2] [3] Obesity is associated with increased morbidity and mortality from cardiovascular disease, type II diabetes, cancer, degenerative diseases of the musculoskeletal system, reproductive disorders and respiratory disorders. The economic burden on society is considerable. Direct costs of obesity in England were estimated at d480 million in 1998 or about 1.5% of National Health Service (NHS) expenditure and indirect costs through lost earnings at d2.1 billion. 2 In the UK, obesity tends to be managed either within the primary care sector in the NHS or in private sector clinics through advice on weight control, diet, physical exercise and lifestyle, although referral to specialist services, drug therapy or very low calorie diets (VLCD) may be considered. Surgery is usually considered for people with morbid obesity when all other measures have failed. Traditionally, these procedures have been viewed with some caution, as they are major surgical procedures associated with significant risk of morbidity and mortality. Recent advances, such as the use of adjustable gastric bands and laparoscopic techniques, have brought renewed interest in the clinical and cost effectiveness of these procedures. In view of the continuing debate, the National Institute for Clinical Excellence (NICE) in the UK, which provides patients, health professionals and the public with guidance on current best practice, was asked to provide national guidance. 4 This paper reports the results of a systematic review and economic evaluation commissioned to assist NICE in their deliberations. Although several reviews have been published, either they were limited in the interventions included, are known not to include recently published evidence or do not consider the cost effectiveness of procedures.
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Methods
We searched for published and unpublished studies in the English language using 14 electronic databases, including Medline, Cochrane library, and Embase from their inception to October 2001(details of search strategy are presented elsewhere and can be obtained from http://www.hta.nhsweb.nhs.uk/fullmono/mon612.pdf)). 11 Additional references were identified through searching bibliographies of related publications and through contact with relevant experts and industry. Studies reported as abstracts or conference presentations were excluded. We included randomised control trails (RCTs), prospective controlled clinical trials, economic evaluations and costing studies of the different surgical procedures for morbid obesity when compared with each other or with nonsurgical interventions. Surgical interventions included jejunoileal bypass, biliopancreatic diversion, gastric bypass, gastroplasty and gastric banding that were used for treating patients diagnosed as morbidly obese, defined as a BMI 440 kg/m 2 , or with a BMI435 kg/m 2 with serious comorbid disease, in whom previous nonsurgical interventions had failed. Although jejunoileal bypass and horizontal gastroplasty procedures are rarely performed in the UK and elsewhere, they were included as opinions differ as to their efficacy and whether recent developments may have overcome apparent limitations. Studies were included if they assessed clinical effectiveness using outcome measures of weight change, fat content, fat distribution, quality of life, peri-and postoperative morbidity and mortality, revision rates and obesity-related comorbidities assessed as primary outcomes at baseline and at least 12 months follow-up. The quality of the studies that met the stated inclusion criteria for the systematic review were assessed using standard components for judging internal validity, 12, 13 and through an adapted method for the external validity of economic evaluations and model bias. 11 Inclusion criteria were applied, data were extracted and quality was assessed by one reviewer and checked by a second reviewer, with any differences resolved through consensus.
To compare clinical and cost effectiveness across different studies, standard information on study characteristics, methods and results was extracted wherever possible for the systematic review (limited data are presented in this article, full details are available elsewhere). 11 Clinical and cost effectiveness were assessed through a narrative comparison of different outcomes. Meta-analysis was precluded due to differences in, or insufficient details on, outcomes used, patient characteristics or intervention used. The economic evaluation developed for this study followed NICE guidance on the conduct of such studies, taking the perspective of the NHS and Personal Social Services for costs and benefits. 4 Sources of costs were restricted to the published information for 1999/2000, 14, 15 with resource use based on scenarios developed from the evidence of clinical effectiveness and expert advice. Efficacy was analysed in terms of change in the health-related quality of life gained from a change in BMI for a stereotypical person (baseline weight 135 kg, BMI 45 kg/m 2 , aged 40 y, life expectancy 20 y) and the impact of comorbidities (restricted to prevalence of diabetes and costs averted from change in medication) derived from studies of clinical effectiveness included in the systematic review. Utility values originate from an economic evaluation of orlistat. 16 The evaluation provided a range of utility values categorised by patient age and BMI, based on time-trade-off values. Although other sources were found, 7, 17 these utility values were thought to be the most comprehensive. Costs and savings were discounted at 6% and quality-adjusted life year (QALYs) at 1.5%. The assumptions underlying the economic evaluation were specific to the UK setting and are summarised in Tables 1 and 2 . These were deliberately biased, within the range of the evidence from the literature and expert opinion, against surgical procedures with the intention of assessing the worst-case Tables 3 and 4 . The methodological quality of the included studies varied (see Table 3 ). Of the 18 studies included to assess clinical effectiveness, seven lacked an adequate description of the method of allocation, 18 
Clinical effectiveness of surgery compared with nonsurgical management
The three studies comparing surgery with nonsurgical management assessed different interventions, specifically horizontal gastroplasty and diet compared with VLCD, 18, 19 jejunoileostomy with medical management [20] [21] [22] and either vertical banded gastroplasty, gastric banding or gastric bypass with nonsurgical management. [23] [24] [25] [26] [27] [28] [29] [30] [31] All three of these studies showed statistically significant weight loss following surgery compared with nonsurgical management at 2 y follow-up, losing between 23 and 37 kg more weight (Table 4) . [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Two studies assessed weight loss beyond 2 y, 
Comparison of different surgical procedures Gastric bypass vs gastroplasty 
Vertical banded gastroplasty vs adjustable gastric banding
Open vs laparoscopic adjustable silicone gastric banding
Surgery for morbid obesity A Clegg et al (Table 4) . 33, 34, 40, 41, [46] [47] [48] [49] [50] [51] [52] [53] In four RCTs the differences in weight loss remained significant beyond 1 y follow-up, to 3 y 40,47-53 and 5 y. 33 None of the RCTs assessed the effects of surgery on quality of life. Three RCTs assessed the effect of surgery on comorbidities at either 1 or 3 y follow-up, 41, [47] [48] [49] [50] [51] [52] [53] showing improvements in diabetes, hypertension, joint pain and asthma. While none of the RCTs reported perioperative deaths, three RCTs reported five postoperative deaths following gastric bypass 34, 40, 53 and one following horizontal gastroplasty. 34 Although complications were common following all forms of surgery, dumping syndrome and heartburn were more evident following gastric bypass than gastroplasty. [47] [48] [49] [50] [51] [52] Revisions, reoperations and/or conversions were more common following gastroplasty (vertical banded gastroplasty 2-53% of patients, horizontal gastroplasty 1-19% of patients) than following gastric bypass (0-39% of patients). [34] [35] [36] 40, 41, [47] [48] [49] [50] [51] [52] [53] Gastric bypass vs jejunoileal bypass. Two RCTs compared gastric bypass with jejunoileal bypass. 32, 39, 43, 44 Although the two RCTs showed slightly greater weight loss (9% or 7 kg more weight loss) following jejunoileal bypass than gastric bypass at 1-y follow-up, differences were not statistically significant (Table 4) . One RCT found that differences continued at 3 y. 39, 43, 44 Quality of life and comorbidities were not assessed by either RCT. Two RCTs reported two postoperative deaths following gastric bypass and one following jejunoileal bypass. Serious complications associated with liver disease affected 80% of the patients undergoing a jejunoileal bypass. 32 Other complications, including wound and urinary tract infection, were evident among gastric bypass and jejunoileal bypass patients. 32, 39, 43, 44 Reoperation, revision or reversal was required by 16% of gastric bypass and 32% of jejunoileal bypass patients. 32, 39, 43, 44 Vertical banded gastroplasty vs horizontal gastroplasty. The one RCT comparing vertical banded gastroplasty with horizontal gastroplasty after pretreatment with VLCD found statistically significant weight loss at 1 y following vertical banded gastroplasty (9.7 kg) but weight gain after horizontal gastroplasty (1 kg) (Table 4) . 45 Quality of life and comorbidities were not assessed. No deaths were reported.
Complications differed little between the procedures, although vertical banded gastroplasty patients suffered significantly more occasional vomiting. 45 Reoperations, revisions and reversals were not reported.
Vertical banded gastroplasty vs adjustable gastric banding. One RCT compared vertical banded gastroplasty with adjustable gastric banding. 38 At 5 y, weight-loss following adjustable gastric banding exceeded that following vertical banded gastroplasty (8 kg difference), although it was not statistically significant (Table 4) . Quality of life and comorbidities were not assessed. One postoperative death was reported following vertical banded gastroplasty and adjustable gastric banding. There was little difference in complications between the procedures. A third of vertical banded gastroplasty patients were reoperated due to staple line disruption or strictures of the stoma, while 10% of adjustable gastric banding patients were reoperated due to gastric pouch dilation.
Open vs laparoscopic gastric bypass.
Two RCTs compared open with laparoscopic gastric bypass. Although the two RCTs showed weight loss following gastric bypass (approximately 30% loss of excess weight), neither RCT found a statistically significant difference in weight loss between the procedures (Table 4) . 37, 54 Early differences in quality of life were assessed using the Short Form Health Survey (SF-36) at 1 month and the Moorehead-Ardelt questionnaire at 3 months that favoured laparoscopic gastric bypass, disappeared at later follow-up (3 and 6 months respectively). 54 One postoperative death was reported following laparoscopic gastric bypass surgery. 37 There were limited differences between the procedures when comparing major, minor and late complications. Reoperations were more common following laparoscopic than open procedures. Although laparoscopic procedures had longer operative times, they caused significantly less blood loss, required shorter intensive care unit stay, shorter hospital stay and shorter time to return to activities of daily living and work.
37,54
Open vs laparoscopic adjustable silicone gastric banding. One RCT 42 compared open and laparoscopic adjustable silicone gastric banding. Although both procedures resulted in statistically significant weight loss at 1-y follow-up (approximately 35 kg), there were no statistically significant differences between the procedures (Table 4 ). Neither quality of life nor comorbidities were assessed. Surgical and early postoperative complications showed limited difference between the procedures. Readmissions and overall length of stay were significantly higher among those undergoing open compared to laparoscopic procedures. A small proportion of laparoscopic patients converted to open procedures.
Systematic review of cost effectiveness of surgery for morbid obesity. Searching found four economic evaluations, three comparing different types of surgery with nonsurgical Surgery for morbid obesity A Clegg et al management and one comparing different types of surgery. 17, [55] [56] [57] The characteristics of, and results from, the economic evaluations are summarised in Table 5 . Judgement of the methodological quality of these economic evaluations was based on standard criteria for internal validity that assess the approaches used to minimise four sources of bias, 12 specifically framing of the model (ie well-defined question, description of alternatives, study type and clinical effectiveness of technology), model construction (ie identification, measuring and credibility of costs and consequences), reliability of estimates used (ie discounting applied, incremental analysis and modelling undertaken appropriately) and the way sensitivity analysis was performed (full details provided elsewhere). 11 Using these criteria, and with limited access to models, one study appeared to be the most robust, only lacking adequate discussion of model construction. 17 The other studies had some inadequacies in model construction, reliability of estimates and sensitivity analysis. [55] [56] [57] Issues concerning external validity were less clear, with all four studies set in different health care systems. As such comparisons between the results of economic evaluations should be made with caution, due in part to the different perspectives adopted and, consequently, the different component costs and benefits included.
Cost effectiveness of surgery in the UK With no relevant cost effectiveness studies available, an economic evaluation was undertaken to consider cost effectiveness in the UK (Tables 1, 2 and Table 6 ). It focused on the three types of surgery that appeared most clinically effective, specifically gastric bypass (Roux-en-Y), vertical banded gastroplasty and adjustable gastric banding, and nonsurgical management. Horizontal gastroplasty and jejunoileostomy were excluded as they are rarely carried out in the UK and jejunoileostomy is widely regarded as unsafe. 58, 59 Comparison of surgery with nonsurgical management showed that surgery offered additional QALYs at an additional cost, with gastric bypass (d6289/QALY), silicone adjustable gastric banding (d8527/QALY) and vertical banded gastroplasty (d10 237/QALY) having net cost per QALY below d11 000. When comparing different surgical procedures the difference was less clear. Gastric bypass appeared to have a modest net cost per QALY gained compared to vertical banded gastroplasty (d742/QALY). In contrast, adjustable silicone gastric banding had large net cost per QALY gained compared to gastric bypass (d256 856/ QALY). However, these incremental cost-effectiveness ratios were based on small differences in clinical effectiveness and should be interpreted with extreme caution. Longer-term follow-up studies are required before a definitive judgement can be made about the most clinically and cost effective surgical technique. Several different scenarios were examined in the one-way sensitivity analyses for gastric bypass surgery compared to nonsurgical management. Increased length of hospital stay to 14 days (d10 323/QALY) increased costs of pre-and postoperative care to include additional surgical outpatient and dietitian follow-up and a VLCD 
Comment
Reasonably good-quality evidence comparing the clinical effectiveness of surgery and nonsurgical management showed that surgery resulted in significantly greater longterm weight loss (23 to 37 kg more weight lost at 2 y with 21 kg difference maintained to 8 y) and improvements in quality of life and comorbidities. Evidence of clinical effectiveness of different surgical procedures was of varying methodological quality. Comparison of the different types of surgery showed that gastric bypass appeared more beneficial, with greater weight loss (6 to 14 kg more weight) and/or improvements in comorbidities and complications than either gastroplasty or jejunoileal bypass. Assessment of open and laparoscopic procedures showed laparoscopic procedures had longer operative time, fewer serious complications, reduced intensive care unit and hospital stay and earlier return to activities of daily living and work. The economic evaluation showed that surgery appears cost effective compared to nonsurgical management assuming a threshold of d30 000, offering additional QALYs at an additional cost under d11 000/QALY. Comparison of the different surgical procedures was less certain. One way sensitivity analyses suggested that surgery compared to nonsurgical management remained cost effective under a range of assumptions. Consistent methods for undertaking systematic reviews were applied, 60 with support from an expert advisory group of clinicians, health professionals and academics. Potential limitations were exclusion of nontrial evidence affecting newer surgical procedures with a limited evidence base, lack of follow-up with authors to clarify study details, and limited information available for the economic evaluation. Possible inadequacies in primary studies may undermine the evidence. Frequently, initial weight loss has been modified by subsequent weight regain. To adequately assess efficacy, studies should have a long-term follow-up, yet only four of 18 studies reported outcomes at 5 y and beyond. Limited attention was given to quality of life with only three of 18 studies including some form of assessment. No account was taken of the role of patient preference for different treatment options, which would affect the implementation of a service. Most studies focused on morbidly obese women aged 30-50 y old. Greater benefits may accrue among younger adults, particularly men. Methodological quality of the studies appeared poor through noncompliance with, or poor reporting of, key aspects of their methods, providing the potential for bias. As a consequence further research should examine the epidemiology of morbid obesity, as well as undertake good quality controlled trials of the different procedures with follow-up beyond 5 y, include quality of life outcomes, and prospective economic evaluations.
Conclusions
Surgery appears to be a clinically and cost-effective treatment for people who are morbidly obese (BMI 440 kg/m 2 ) or have a BMI 435 kg/m 2 with significant comorbid conditions. Due to the nature of the evidence, particularly the uncertainty in the economic evaluation, it is difficult to distinguish between the different procedures. With evidence continuing to emerge, we recommend that our findings are periodically reviewed and revised.
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